Background/Aims: Deep infiltrating endometriosis is a very painful condition and the mechanism of pain is still poorly understood. Pain and hyperalgesia can partly be explained by an increased number of nerve structures in the painful lesion. In order to clarify this issue, we assessed the nerve density in deep infiltrating endometriotic nodules of the posterior vagina and in the adjacent healthy vaginal tissue of the same patient. Methods: A prospective clinical and pathological study of 31 cases of deep infiltrating vaginal endometriotic nodules was conducted. Fifteen patients were in the proliferative phase and 16 in the secretory phase. The nerve density was studied by immunohistochemistry with the monoclonal antibody NF against neurofilaments in deep infiltrating endometriosis and in the adjacent unaffected vaginal tissue in the proliferative and in the secretory phases. Neurofilaments constitute the main structural elements of neuronal axons and dendrites. Results: The nerve density was significantly different in the endometriotic nodule than in the adjacent unaffected vaginal tissue (p = 0.0013). The same significant difference was found between endometriotic nodules and the unaffected vagina in the proliferative phase (p = 0.009) and in the secretory phase (p = 0.04). This difference was not significant between the proliferative and the secretory phases in the endometriotic lesions and in the controls. Conclusions: We hypothesize that the significantly increased number of nerve structures in the endometriotic nodules may contribute to the occurrence of severe and neuropathic pain that characterizes these lesions

Keywords:
Nerves, Neurofilaments, Pain, Deep infiltrating endometriosis
1.
Chapron C, Fauconnier A, Dubuisson JB, Barakat H, Vieira M, Bréart G: Deeply infiltrating endometriosis: relation between severity of dysmenorrhoea and extent of the disease. Hum Reprod 2003;18:760–766.
2.
Anaf V, Simon P, El Nakadi I, et al: Impact of surgical resection of rectovaginal pouch of Douglas endometriotic nodules on pain and some elements of patient’s sex life. J Am Assoc Gynecol Laparosc 2001;8:55–60.
3.
Horowitz SH: The diagnostic workup of patients with neuropathic pain. Med Clin North Am 2007;91:21–30.
4.
Warfield CA, Fausett HJ: Manual of Pain Management. Philadelphia, Lippincott Williams & Wilkins, 2002.
5.
Anaf V, Simon P, El Nakadi I, Fayt I, Buxant F, Simonart T, Peny MO, Noel JC: Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod 2000;15:1744–1750.
6.
Scholz J, Woolf CJ: Can we conquer pain? Nat Neurosci 2002;5(suppl):1062–1067.
7.
Woolf CJ: Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 2004;74:2605–2610.
8.
Anaf V, Chapron C, El Nakadi I, De Moor V, Simonart T, Noel JC: Pain, mast cells and nerves in peritoneal, ovarian and deep infiltrating endometriosis. Fertil Steril 2006;86:1336–1343.
9.
Witzel C, Rohde C, Brushart TM: Pathway sampling by regenerating peripheral axons. J Comp Neurol 2005;485:183–190.
10.
Jenq CB, Coggeshall RE: Long-term patterns of axon regeneration in the sciatic nerve and its tributaries. Brain Res 1985;345:34–44.
11.
Noyes RW: Normal phases of the endometrium; in Norris HJ, Hertig AT, Abbel MR (eds): The Uterus. Baltimore, Williams & Wilkins, 1973, pp 110–135.
12.
Donnez J, Nisolle M, Casanas-Roux F, Bassil S, Anaf V: Rectovaginal septum endometriosis or adenomyosis: laparoscopic management in a series of 231 patients. Hum Reprod 1995;10:630–635.
13.
Osborn M, Dirk T, Kaser H, et al: Immunohistochemical localization of neurofilaments and neuron-specific enolase in 29 cases of neuroblastoma. Am J Pathol 1986;122:433–442.
14.
Altmannsberger M, Osborn M, Droese M, et al: Diagnostic value of intermediate filament antibodies in clinical cytology. Klin Wochenschr 1984;62:114–123.
15.
Debus E, Weber K, Osborn M: Monoclonal antibodies specific for glial fibrillary acidic (GFA) protein and for each of the neurofilament triplet polypeptides. Differentiation 1983;25:193–203.
16.
Shaw G, Osborn M, Weber K: Reactivity of a panel of neurofilament antibodies on phosphorylated and dephosphorylated neurofilaments. Eur J Cell Biol 1983;42:1–9.
17.
Sumathi VP, McCluggage WG: CD10 is useful in demonstrating endometrial stroma at ectopic sites and in confirming a diagnosis of endometriosis. J Clin Pathol 2002;55:391–392.
18.
Onda T, Ban S, Shimizu M: CD10 is useful in demonstrating endometrial stroma at ectopic sites and in confirming a diagnosis of endometriosis. J Clin Pathol 2003;56:78–80.
19.
Clement PB, Young RH: Two previously underemphasized features of endometriotic micronodular stromal endometriosis and endometriosis with stromal elastosis. Int J Surg Pathol 2000;8:223–227.
20.
Chalkley HW: Method for the quantitative morphologic analysis of tissues. J Nat Cancer Instit 1943;4:47–53.
21.
Hansen S, Grabau DA, Rose C, Bak M, Sorensen FB: Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 1998;78:1563–1573.
22.
Wang G, Tokushige N, Markham R, Fraser IS: Rich innervation of deep infiltrating endometriosis. Hum Reprod 2009;24:827–834.
23.
Apfel CC: Neurotrophic factors and pain. Clinical J Pain 2000;16:S7–S11.
24.
Kessler JA, Black IB: Nerve growth factor stimulates the development of substance P in sensory ganglia. Proc Natl Acad Sci USA 1980;77:649–652.
25.
Pezet S, Mc Mahon SB: Neurotrophins: mediators and modulators of pain. Ann Rev Neurosci 2006;29:507–538.
26.
Filogamo G, Cracco C: Models of neuronal plasticity and repair in the enteric nervous system: a review. Ital J Anat Embryol 1995;100:185–195.
27.
Filogamo G, Vigliani F: Les cellules du plexus myentérique (d’Auerbach) dans la sténose experimentale de l’intestin. CR Assoc Anat 1953;78:683–692.
28.
Fauconnier A, Chapron C: Endometriosis and pelvic pain: epidemiologic evidence of the relationship and implications. Hum Reprod Update 2005;11:595–606.
29.
Farquhar C: Endometriosis. BMJ 2007;304:49–253.
30.
Sturgis SH, Call BJ: Endometriosis peritonei; relationship of pain to functional activity. Am J Obstet Gynecol 1954;68:1421.
31.
Chapron C, Liaras E, Fayet P, Hoeffel C, Fauconnier A, Vieira M, Barakat H, Dousset B, Legmann P, Bonnin A, Dubuisson JB: Magnetic resonance imaging and endometriosis: deeply infiltrating endometriosis does not originate from the rectovaginal septum. Gynecol Obstet Invest 2002;53:204–208.
32.
Anaf V, Buxant F, Rodesch F, Simon P, Van de Stadt J, Noel J-C, Van Geertruyden J: Adenoid cystic carcinoma of the Bartholin’s gland: what is the optimal approach? Eur J Surg Oncol 1999;26:406–409.
33.
Remorgida V, Ragni N, Ferrero S, Anserini P, Torelli P, Fulheri E: The involvement of the intersitial Cajal cells and the enteric nervous system in bowel endometriosis. Hum Reprod 2005;20:264–271.
34.
Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D: Is endometriosis associated with systemic subclinical inflammation. Gynecol Obstet Invest 2006;62:139–147.
35.
Tokushige N, Markham R, Russell P, Fraser IS: Effects of progestogens and combined oral contraceptives on nerve fibers in peritoneal endometriosis. Fertil Steril 2009;92:1234–1239.
36.
Smith PG, George M, Bradshaw S: Estrogen promotes sympathetic nerve regeneration in rat proximal urethra. Urology 2009;73:1392–1396.
37.
Leonelli E, Ballabio M, Consoli A, Roglio I, Magnaghi V, Melcangi RC: Neuroactive steroids: a therapeutic approach to maintain peripheral nerve integrity during neurodegenerative events. J Mol Neurosci 2006;28:65–76.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.